Evogene Ltd.

Ladies and gentlemen, thank you for standing by. Welcome to Evagen's second quarter 2021 results conference call. All participants are present in listen-only mode. Following management's formal presentation, instructions will be given for the question and answer session. For operator assistance during the conference, please press star zero. As a reminder, this conference is being recorded August 11, 2021. Before we begin, I would like to caution that certain statements made during this earnings conference call by Evagen's management will constitute forward-looking statements that relate to future events, risks, and uncertainties regarding business strategy, operations, and future performance and results of Evogen. I encourage you to review Evogen's filings with the U.S. Securities and Exchange Commission and read the note regarding forward-looking statements in today's earnings release, which states that statements made in the earnings release and in a similar way on this earnings conference call that are not historical facts may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For example, Evagen is using forward-looking statements in this call when it discusses its expected paths to value creation and its belief that turning one or more of its subsidiaries into public companies will be beneficial to its shareholders. Evagen's and its subsidiaries' expected trials, studies, product advancements, commercializations, launches, pipelines, milestones, potential collaborations, cash usage, and other plans for 2021 and 2022, the potential advantages of its technology and its anticipated entry into new fields of activity. All forward-looking statements made herein speak only as of the date of the announcement of results. Many of the factors that impact whether forward-looking statements will come true are beyond the control of Evagen and may cause actual results to differ materially from anticipated results. Evagen is under no obligation to update publicly or alter our forward-looking statements, whether as a result of new information, future events, or otherwise, except as otherwise required by law. We expressly disclaim any obligation to do so. More detailed information about the risk factors potentially adversely impacting our performance can be found in our reports filed with the U.S. Securities and Exchange Commission. That said, I would now like to turn the call over to Ofer Haviv, Evagen's CEO.

Ofer, please go ahead. Thank you and good day, everyone. We appreciate your joining us today for our second quarter 2021 conference call. Joining me today are Ms. Sarit Firon, Evogen's new chairperson, and Ms. Dorit Reiner, our CFO. Sarit will start the conference call with a short introduction and provide her vision of the Evogen Group. I will then discuss our plan for unlocking the value of our subsidiaries and provide an overview of our recent achievements. Dorit will summarize Evogen's financial results for the second quarter and first half of 2021. We will then open the call for your questions. Before I hand over to Sarit, our new chairperson, I would like to address Martin Gristel, our former chairman. As you know, in June this year, after two decades of chairing Evogen since our founding, Martin felt he should take a well-deserved retirement from Evogen. I would like to take this opportunity To thank Martin wholeheartedly for his constant leadership and vision as our chairperson and his ongoing invaluable contribution to Evogen's development and on a personal note, I would also like to thank him for his guidance and support of me in the role of a CEO. I would like to welcome Sarit as Evogen's new chairperson. Sarit has been a highly effective member of our board since 2016 and knows Evogen and its subsidiaries very well, which will ensure a smooth transition into her new role as chairperson of the board. Sarit brings to Evogen more than 27 years of global investment and operational experience across Silicon Valley, New York, and Tel Aviv. She is one of Israel's most accomplished investors and is well known for helping to build companies from their early stage to successful IPOs and acquisitions. Sarit currently serves as the managing partner of the Team 8 Group and managing partner of the Team 8 Capital, the investment arm of the Group. She has held numerous operational and leadership roles. Serving as chairperson and board member, CEO and CFO at prominent high-tech companies. I cannot think of anyone better suited to assume the role of a chairperson at the present time and I'm truly excited that she has agreed to this role. On behalf of all the management, employees and investors in Evogen, I would like to wish her much success. Sarit, please.

Thank you, Ofer, for your warm introduction. I'm honored to have the opportunity to lead Evergene as its new chairperson. Evergene is an extraordinary company with highly differentiated predictive discovery and development capabilities and an impressive product pipeline through its subsidiaries. I look forward to working with my fellow directors, Ofer, and the entire senior management team. Together, we will take Evergene and its subsidiaries to the next level in value creation and subsequently gained recognition by the capital market. I would like to join Ofer in thanking Martin for his significant contribution made to Evergine since its inception. Martin should be extremely proud of Evergine's journey from its establishment to where we are today, as one of the key leaders that built the foundation for a promising future ahead. Our vision is to change the way life science companies are developing their products to substantially increase the probability of success and at the same time reducing the time and cost of life science product development. To execute this vision, our strategy is to focus on utilizing the most advanced computational biology we developed. Over the last two decades, Imogen has developed a unique computational predictive biology platform and an investment of tens of millions of dollars incorporating deep scientific understanding together with big data and artificial intelligence. We then established subsidiaries who have developed strong product pipelines very rapidly by utilizing this advanced technology. And now our subsidiaries are reaching a level of maturity where their underlying value is becoming apparent. As Ofer stated in his introduction, Throughout my career, I've taken companies to the next level by realizing their value potential through IPO, acquisition, or other financial transactions. I'm excited to bring this experience to Evergen and its subsidiaries to help in unlocking the inherent value in each individual subsidiary. We will ensure that each subsidiary is focused on its key strengths, which will enable you to realize its unique values. Ofer will elaborate on our strategy later in the call. From now, I would like to hand it over to Ofer and I look forward to continuing updating you about our progress and achievements in the future. Ofer, back to you.